Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The pathologist's perspective on the PCPT trial].

V Molinié1, Y Allory

  • 1Service de Pathologie, Hôpital Saint-Joseph, 185 Rue Raymond-Losserand, Paris, France. vmolinie@hpsj.fr

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|September 26, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification.

ESMO real world data and digital oncology·2026
Same author

French AFU Cancer Committee Guidelines - Update 2024-2026: Upper urinary tract urothelial cancer (UTUC).

The French journal of urology·2024
Same author

Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC).

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same author

French AFU Cancer Committee Guidelines - Update 2022-2024: Muscle-Invasive Bladder Cancer (MIBC).

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same journal

["Connected device for monitoring patients treated by prostatectomy: Implementation and qualitative assessment"].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Role of nurses specializing in oncology to support the care journey for patients with penile cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Pre- and post-prostatectomy rehabilitation by the certified nurse-urologist pair (REHAB): Feasibility study].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Genitourinary complications after pelvic radiotherapy: Diagnosis and management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same journal

[Male contraception].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
See all related articles

Finasteride reduced prostate cancer incidence but paradoxically increased high-grade diagnoses. Further analysis revealed no increased cancer aggressiveness, suggesting biopsy overestimation in finasteride-treated men.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • The Prostate Cancer Prevention Trial (PCPT) investigated finasteride's efficacy in reducing prostate cancer.
  • Finasteride (5 mg/d) was compared against a placebo in men over 55.
  • A key observation was a paradoxical increase in high-grade cancer diagnoses in the finasteride group.

Purpose of the Study:

  • To investigate the reasons behind the increased incidence of high-grade prostate cancers observed in the finasteride arm of the PCPT.
  • To determine if finasteride promotes the development of more aggressive prostate cancer.
  • To assess the impact of finasteride on Gleason score interpretation.

Main Methods:

  • Analysis of histological findings from radical prostatectomy specimens.

Related Experiment Videos

  • Comparison of Gleason scores from biopsy and prostatectomy specimens.
  • Evaluation of cancer aggressiveness in both finasteride and placebo groups.

    • Main Results:

    • Histological review indicated an overestimation of Gleason scores on biopsy in both finasteride and placebo groups.
    • High-grade cancers identified in prostatectomy specimens were not more aggressive in the finasteride arm.
    • No evidence suggests long-term finasteride use promotes highly aggressive cancer development.

    Conclusions:

    • Finasteride treatment may lead to morphological changes affecting Gleason score interpretation.
    • Pathologists must be informed about finasteride use to ensure accurate Gleason scoring.
    • A double-reading protocol for high-grade cancers in finasteride-treated patients is recommended.